Furey John 4

What Happened

• John Furey, a director of Vaxcyte, received equity awards on June 15, 2026. The filing shows two entries: 2,265 shares acquired at $0 and 11,389 derivative shares acquired at $0 (reported as RSU/derivative). Combined, the awards total 13,654 shares/units; the grant price reported is $0 (compensation award rather than an open‑market purchase).

Key Details

• Transaction date: June 15, 2026; filing date: June 16, 2026 (timely under Section 16 filing rules).
• Reported amounts: 2,265 shares (non‑derivative) and 11,389 derivative shares (RSUs), both at $0 per share.
• Shares owned after the transaction: Not specified in the filing.
• Footnotes from the filing:
  • F1: The derivative shares represent RSUs. Each RSU is the contingent right to receive one share of common stock; these RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration and continuous service.
  • F2: The shares subject to the other award (option/award) will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting, subject to acceleration and continuous service.
• No 10b5‑1 plan, tax‑withholding sale, or late filing flags were noted in the entry.

Context

• These are compensation awards (grants/RSUs/options) rather than purchases or sales. RSUs/derivative awards are rights to receive shares in the future if vesting conditions are met; the reported $0 price reflects the grant, not market value. Such grants are common for directors and reflect compensation, not an immediate market trade or direct sentiment signal.